Pharmafile Logo

Leveraging virtual tools to get the most out of hybrid congresses

Tips on how to optimize congress information-gathering…

The COVID-19 pandemic turned virtual congresses from a relatively rare occurrence to a must-have in 2020. While we saw some attempts at hybrid and in-person events in 2021, 2022 was the year that hybrid congresses and conferences finally became a mainstay across the medical and scientific communities. Although this format adds a layer of complexity for the organizers, it’s a win-win situation for presenters and attendees alike. I could dedicate an entire separate article to the benefits of hybrid congresses for the environment, attendee convenience, and budget alone!

With the shift to hybrid conferences, you can now watch sessions you missed on-demand and visit all posters on your own time. However, the large amount of data being presented and multiple simultaneous sessions can make it hard to focus the attendees’ attention. As a result, it becomes difficult to gather targeted feedback. For Pharma, getting all of their key opinion leaders (KOLs) in one room to get their thoughts on the new data presented during the congress can often prove difficult due to scheduling conflicts or some KOLs attending the conference virtually. Other healthcare providers (HCPs) may not attend at all due to time or financial constraints.

If you, like many other life science leaders, are struggling with coordinating, documenting, following up on, and disseminating clear, relevant insights from congresses, access the rest of this article for my tips on how to optimize congress information-gathering.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Helping Caregivers Stay Organized, Secure, and Informed

Audrey Bond, Founder & CEO of Vaultt, discusses her inspiration behind founding the company, how Vaultt is revolutionizing data-sharing in Canada, common biosecurity and data privacy concerns, her experience with...

Transitioning to the “New Normal”: What This Means for Oncology Care

Dr. Burt Zweigenhaft, Co-founder of the Association for Value-Based Cancer Care, shares his thoughts on the importance of patient-centricity in cancer care, current barriers to value-based care in the US...

Making Wearable Technology Scalable and Adoptable

Ilaria Varoli, EVP of Myant Inc., explores Textile Computing™ for remote monitoring, health assessments, pediatric and maternal care, temperature regulation, monitoring of athlete performance, and much more.

Courageous Conversation ep.12: Not Going Back: How COVID Has Changed Clinical Trials

Natalie Yeadon, CEO & Co-Founder at Impetus Digital, provides insight into how COVID has changed clinical trials.

Courageous Conversation ep.11: How to Inspire Creativity with Virtual Working Groups

Natalie Yeadon, Co-Founder & CEO at Impetus Digital, provides insight on how to inspire creativity with virtual working groups.

Parallel HCP-Patient Advisory Boards: A Customer Story

Learn how a Pharma team engaged both dermatologists and patients with psoriasis in two parallel virtual advisory boards.

Courageous Conversation ep.10: Facial Recognition Software in Healthcare

Natalie Yeadon, Co-Founder & CEO at Impetus Digital, provides insight on Facial Recognition Software in Healthcare.

Transforming the Future of Health & Aging from a Global Health & Social Impact Approach

Dr. Zayna Khayat, Future Strategist at SE Health, dives into the future of aging and healthcare in Canada, including the roles of emerging technologies, the shift to people-powered healthcare, and...

Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery

Dr. Shahar Keinan, Co-founder & CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve...

Top-10 ways that Pharma teams can fight the climate crisis

Ten easy steps that individual medical, marketing, clinical, regulatory, and market access teams can take to reduce their own footprints.